CTLA4 and cancer: Blocking CTLA-4 is more suitable for treating cancers with low levels of glycolysis, while for cancers with high levels of glycolysis, the combination of anti-CTLA-4 antibodies with glycolysis inhibitors increases the availability of glucose in the TME, which maximizes Treg cell instability and enhances anticancer immunity [306].